MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.

Even though anti-interferon beta (IFNβ) antibodies are the main determinants of IFNβ bioactivity loss and Myxovirus-resistance protein A (MxA) is the most established marker of IFNβ biological activity in IFNβ-treated multiple sclerosis patients, their usefulness in the routine clinical practice is...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Federico Serana, Luisa Imberti, Maria Pia Amato, Giancarlo Comi, Claudio Gasperini, Angelo Ghezzi, Vittorio Martinelli, Leandro Provinciali, Maria Rosa Rottoli, Stefano Sotgiu, Sergio Stecchi, Michele Vecchio, Mauro Zaffaroni, Cinzia Cordioli, Ruggero Capra
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Public Library of Science (PLoS) 2014-01-01
Σειρά:	PLoS ONE
Διαθέσιμο Online:	http://europepmc.org/articles/PMC3986392?pdf=render
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!